Santhera Pharmaceuticals Holding AG (S3F0)
XSTU
14.72
-0.88 (-5.64%)
Closed
Oct 13, 2026
Day's Range
14.6215.66
52 wk Range
10.0220.25
Financial Statements - S3F0 - Santhera Pharmaceuticals Holding AG
Revenue
77.18M▲ 97.3%
Net Income
-49.23M▼ 17.3%Net Margin -63.8%
EBITDA
-35.05M▼ 42.0%
Free Cash Flow
-34.81M▲ 2.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 77.18M | 39.11M | 103.41M | 7.47M | -1.59M | 15M |
| Cost of Goods | 62.01M | 15.53M | 3.23M | 3.59M | 3.76M | 10.43M |
| Gross Profit | 15.17M | 23.58M | 100.17M | 3.88M | -5.36M | 4.57M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -37.61M | -33.15M | 51.16M | -51.97M | -56.88M | -53.07M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | -49.05M | -41.66M | 54.82M | -70.61M | -54.71M | -67.45M |
| Income Tax | 185K | 312K | 38K | 460K | 809K | 203K |
| Net Income | -49.23M | -41.97M | 54.78M | -71.07M | -55.52M | -67.65M |
| EPS Basic | -3.78 | -3.69 | 5.18 | -11.67 | -16.2 | -50.8 |
| EPS Diluted | -3.78 | -3.69 | 5.01 | -11.67 | -16.2 | -50.8 |
| Basic Shares Outstanding | 13.01M | 11.38M | 10.57M | 6.09M | 3.19M | 1.33M |
| Diluted Shares Outstanding | 13.01M | 11.38M | 10.57M | 6.09M | 3.19M | 1.33M |
| Ebit | -37.49M | -33.88M | 76.13M | -50.42M | -38.29M | -60.56M |
| Ebitda | -35.05M | -24.68M | 53.46M | -42.49M | -56.66M | -53.92M |
| Net Income Continuous Operations | -49.05M | -41.66M | 54.82M | -70.61M | -54.71M | -67.45M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
